Using advanced MRI to predict how pancreatic cancer patients respond to treatment
Translating Hyperpolarized 13C MRI as a Novel Tool to Predict Treatment Response in Pancreatic Cancer
This study is testing a new imaging technique to help doctors see how well treatments are working for patients with pancreatic cancer, so they can make better decisions about care and potentially improve outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11002701 on NIH RePORTER |
What this research studies
This research aims to develop a novel imaging technique using hyperpolarized 13C MRI to monitor and predict treatment responses in patients with pancreatic ductal adenocarcinoma (PDA). By utilizing this advanced imaging method, the study seeks to provide more accurate and timely assessments of how well patients are responding to therapies, particularly in cases where surgery may be an option. The goal is to improve clinical decision-making by identifying effective treatments sooner and potentially guiding patients towards better outcomes. This approach addresses the limitations of current assessment tools that often fail to provide early indicators of treatment efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with localized disease who may be eligible for neoadjuvant therapy.
Not a fit: Patients with advanced, non-resectable pancreatic cancer who are not candidates for surgery may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for patients with pancreatic cancer, ultimately improving survival rates.
How similar studies have performed: Similar research using advanced imaging techniques has shown promise in other cancer types, suggesting that this approach could be beneficial for pancreatic cancer as well.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Gordon, Jeremy William — University of California, San Francisco
- Study coordinator: Gordon, Jeremy William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.